1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Holly LaFon
Holly LaFon
Articles (8474) 

Bernard Horn Comments on Teva Pharmaceutical

Guru stock highlight

April 16, 2018 | About:
Teva Pharmaceutical (NYSE:TEVA) continued to face headwinds, with sluggish generic product introductions and pricing pressures. With a new CEO at the helm, Teva launched a comprehensive restructuring plan to shore up its balance sheet. The company enacted layoffs and plant closures, optimized its generics portfolio and reviewed of its R&D and drug pipeline. Consistent with this agenda, Teva announced the termination of its CGRP migraine drug discovery and development pact with Sosei. The company also renegotiated some of its debt at much higher interest rates than previous. Neither of these actions was well received by the market.

From Bernard Horn (Trades, Portfolio)'s first quarter 2018 shareholder letter.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by Holly LaFon


User Generated Screeners


DANGORDON4-8-18 PORTFOLIO
danccchanIndustry Research
danccchanValue Investing
JoeKafkaROC35
comundongoBen Graham NNWC Screen Updated
comundongoBen Graham NNWC Screen Updated
DANGORDON4-18-18 MONSTER STOCKS
clemclem_99clemsPF
DBrizanQUAL18Apr2018 1056p
DBrizanQUAL18Apr2018 1034p
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK